Home › Funds › ACUTA CAPITAL PARTNERS, LLC › OCUL
ACUTA CAPITAL PARTNERS, LLC position in OCUL
OCULAR THERAPEUTIX INC · Health Care
ACUTA CAPITAL PARTNERS, LLC reported holding 574,543 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 3.48% of its reported portfolio and ranking #9 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed OCUL holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ACUTA CAPITAL PARTNERS, LLC's OCUL position evolved
ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in OCUL in Q4 2023 at 1,310,000 shares (US$5.8M). The position peaked in Q1 2024 at 2,635,287 shares, worth US$24.0M. Across 12 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 574,543 shares valued at US$4.4M — an increase of 42,062 shares quarter over quarter.. Notable position changes include a 101% increase in Q1 2024 (shares fell 25% over the following quarter), a 57% trim in Q3 2024 (shares fell 2% over the following quarter), a 44% trim in Q1 2026 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 1.31M | $5.84M | New |
| Q1 2024 | 2.64M | $23.98M | Add |
| Q2 2024 | 2.77M | $18.95M | Add |
| Q3 2024 | 1.19M | $10.35M | Reduce |
| Q4 2024 | 1.11M | $9.49M | Reduce |
| Q1 2025 | 1.22M | $8.94M | Add |
| Q2 2025 | 1.01M | $9.42M | Reduce |
| Q3 2025 | 1.17M | $13.62M | Add |
| Q4 2025 | 1.05M | $12.78M | Reduce |
| Q1 2026 | 592.11K | $5.02M | Reduce |
| Q2 2026 | 532.48K | $5.23M | Reduce |
| Q3 2026 | 574.54K | $4.41M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCUL and 13F data
OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 34 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$168.3M), Venrock Adviser, LLC (US$101.6M), SUMMER ROAD LLC (US$95.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCUL
- Deep Track Capital, LP 21.94M sh · $168.28M · Q3 2026
- Venrock Adviser, LLC 10.35M sh · $101.61M · Q2 2026
- SUMMER ROAD LLC 12.46M sh · $95.59M · Q3 2026
- Avoro Capital Advisors LLC 12.38M sh · $94.96M · Q3 2026
- Logos Global Management LP 6.00M sh · $46.02M · Q3 2026
- Octagon Capital Advisors LP 2.08M sh · $20.38M · Q2 2026
- DELTEC ASSET MANAGEMENT LLC 2.62M sh · $20.12M · Q3 2026
- Defilade Capital Management, L.P. 1.49M sh · $14.63M · Q2 2026
- Boxer Capital Management, LLC 1.30M sh · $12.77M · Q2 2026
- Knoll Capital Management, LLC 1.15M sh · $11.30M · Q2 2026
More on ACUTA CAPITAL PARTNERS, LLC
FAQ
How long has ACUTA CAPITAL PARTNERS, LLC held OCUL?
ACUTA CAPITAL PARTNERS, LLC has disclosed OCUL holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is ACUTA CAPITAL PARTNERS, LLC's current position in OCUL?
As of Q3 2026, ACUTA CAPITAL PARTNERS, LLC holds 574.54K shares of OCUL (OCULAR THERAPEUTIX INC), valued at $4.41M, representing 3.48% of its reported portfolio and ranking #9.
Has ACUTA CAPITAL PARTNERS, LLC been buying or selling OCUL?
In the latest 13F filing (Q3 2026), ACUTA CAPITAL PARTNERS, LLC increased its position in OCUL. The position peaked in Q1 2024 at 2.64M shares.
Which other funds hold OCUL?
Other major institutional holders of OCUL include Deep Track Capital, LP, Venrock Adviser, LLC, SUMMER ROAD LLC, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.